Skip Navigation

Aymen Elfiky, MD, MSc, MBA


Medical Oncology

Make an Appointment

Physician

  • Physician
  • Instructor in Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Adrenal cancer
  • Adrenocortical carcinoma (ACC)
  • Biomedical informatics
  • Bladder cancer
  • Hospital-based cancer care coordination
  • Kidney cancer
  • Process Improvement
  • Prostate cancer
  • Renal cell carcinoma
  • Technology-enabled care
  • Testicular cancer
  • Total quality management

Contact Information

  • Appointments877-332-4294
  • Office Phone Number617-632-5945
  • Fax617-394-2994

Board Certification:

  • Internal Medicine
  • Medical Oncology

Fellowship:

  • Dana-Farber/Partners CancerCare, Medical Oncology
  • Yale Cancer Center

Residency:

  • New York University Medical Center, Internal Medicine
  • Yale-New Haven Hospital

Medical School:

  • Washington University School of Medicine

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston MA, 02215
Get Directions

Research

Antonarakis ES, Kibel AS, Yu EY, Karsh LI, Elfiky A, Shore ND, Vogelzang NJ, Corman JM, Millard FE, Maher JC, Chang NN, DeVries T, Sheikh NA, Drake CG. Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial. Clin Cancer Res. 2017 May 15; 23(10):2451-2459.
View in: PubMed

Oh B, Figtree G, Costa D, Eade T, Hruby G, Lim S, Elfiky A, Martine N, Rosenthal D, Clarke S, Back M. Oxidative stress in prostate cancer patients: A systematic review of case control studies. Prostate Int. 2016 Sep; 4(3):71-87.
View in: PubMed

Elfiky AA, Krishnan Nair HK. Assessment and management of advanced adrenocortical carcinoma using a precision oncology care model. Discov Med. 2016 Jan; 21(113):49-56.
View in: PubMed

Muralidhar V, Regan MM, Werner L, Nakabayashi M, Evan CP, Bellmunt J, Choueiri TK, Elfiky AA, Harshman LC, McKay RR, Pomerantz MM, Sweeney CJ, Taplin ME, Kantoff PW, Nguyen PL. Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. Clin Genitourin Cancer. 2016 Aug; 14(4):e299-305.
View in: PubMed

Elfiky A. Adrenocortical Carcinoma: A Clinician's Perspective. Surg Pathol Clin. 2015 Dec; 8(4):751-4.
View in: PubMed

Elfiky A, Zhang D, Krishnan Nair HK. Practice innovation: the need for nimble data platforms to implement precision oncology care. Discov Med. 2015 Jul-Aug; 20(108):27-32.
View in: PubMed

Agboola SO, Ju W, Elfiky A, Kvedar JC, Jethwani K. The effect of technology-based interventions on pain, depression, and quality of life in patients with cancer: a systematic review of randomized controlled trials. J Med Internet Res. 2015 Mar 13; 17(3):e65.
View in: PubMed

Fay AP, Signoretti S, Callea M, Tel? GH, McKay RR, Song J, Carvo I, Lampron ME, Kaymakcalan MD, Poli-de-Figueiredo CE, Bellmunt J, Hodi FS, Freeman GJ, Elfiky A, Choueiri TK. Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. J Immunother Cancer. 2015; 3:3.
View in: PubMed

Agboola S, Flanagan C, Searl M, Elfiky A, Kvedar J, Jethwani K. Improving outcomes in cancer patients on oral anti-cancer medications using a novel mobile phone-based intervention: study design of a randomized controlled trial. JMIR Res Protoc. 2014 Dec 23; 3(4):e79.
View in: PubMed

Courtney KD, Manola JB, Elfiky AA, Ross R, Oh WK, Yap JT, Van den Abbeele AD, Ryan CW, Beer TM, Loda M, Priolo C, Kantoff P, Taplin ME. A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer. Clin Genitourin Cancer. 2015 Apr; 13(2):113-23.
View in: PubMed

Porter JM, Barysauskas C, Mach SL, Rodgers E, Elfiky A, Jacobson JO, Jackman DM. Development and implementation of clinical pathways in lung cancer at an academic comprehensive cancer center. J Clin Oncol. 2014 Oct 20; 32(30_suppl):98.
View in: PubMed

Perry L, Bartel S, Elfiky A, Kaymakcalan MD, Murphy K, Jacobson JO, Dalby CK. Standardizing risk: Development of disease and regimen-specific side effect language to enhance consent and chemotherapy treatment plan. J Clin Oncol. 2014 Oct 20; 32(30_suppl):162.
View in: PubMed

Ziehr DR, Mahal BA, Aizer AA, Hyatt AS, Beard CJ, D Amico AV, Choueiri TK, Elfiky A, Lathan CS, Martin NE, Sweeney CJ, Trinh QD, Nguyen PL. Income inequality and treatment of African American men with high-risk prostate cancer. Urol Oncol. 2015 Jan; 33(1):18.e7-18.e13.
View in: PubMed

Smith MR, Sweeney CJ, Corn PG, Rathkopf DE, Smith DC, Hussain M, George DJ, Higano CS, Harzstark AL, Sartor AO, Vogelzang NJ, Gordon MS, de Bono JS, Haas NB, Logothetis CJ, Elfiky A, Scheffold C, Laird AD, Schimmoller F, Basch EM, Scher HI. Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. J Clin Oncol. 2014 Oct 20; 32(30):3391-9.
View in: PubMed

Fay AP, Elfiky A, Teló GH, McKay RR, Kaymakcalan M, Nguyen PL, Vaidya A, Ruan DT, Bellmunt J, Choueiri TK. Adrenocortical carcinoma: the management of metastatic disease. Crit Rev Oncol Hematol. 2014 Nov; 92(2):123-32.
View in: PubMed

Mahal BA, Ziehr DR, Aizer AA, Hyatt AS, Lago-Hernandez C, Choueiri TK, Elfiky AA, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Kim SP, Lathan CS, Trinh QD, Nguyen PL. Racial disparities in an aging population: the relationship between age and race in the management of African American men with high-risk prostate cancer. J Geriatr Oncol. 2014 Oct 01; 5(4):352-8.
View in: PubMed

Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG, Stewart M, Choueiri TK, Gandhi L, Cleary JM, Elfiky AA, Taplin ME, Stack EC, Signoretti S, Loda M, Shapiro GI, Sabatini DM, Lander ES, Gabriel SB, Kantoff PW, Garraway LA, Rosenberg JE. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 2014 May; 4(5):546-53.
View in: PubMed

Waldman LT, Svoboda L, Young BF, Abel GA, Berlin S, Elfiky AA, Freedman RA, Drews M, Holland L, Lathan CS. A novel community-based delivery model to combat cancer disparities. Healthc (Amst). 2013 Dec; 1(3-4):123-9.
View in: PubMed

Waldman LT, Bean W, Levine AL, Cohen-Bearak A, Phelps FA, Svoboda L, Freedman R, Elfiky A, Berlin S, Abel GA, Deutsch C, Lathan CS. Using FastTrack to Implement an Academic Medical Center and Community Health Center Collaborative for Cancer Care Delivery. Healthc (Amst). 2013 Dec; 1(3-4):130-135.
View in: PubMed

Chen J, Elfiky A, Han M, Chen C, Saif MW. The role of Src in colon cancer and its therapeutic implications. Clin Colorectal Cancer. 2014 Mar; 13(1):5-13.
View in: PubMed

Kaymakcalan M, Elfiky A, Dalby CK, Bryar JM, Jacobson JO. Improving quality and safety of oncology patient care: Standardization of the post-clinic message triage process. J Clin Oncol. 2013 Nov; 31(31_suppl):163.
View in: PubMed

Jacobus SJ, Qu AQ, Sweeney C, Appleman LJ, Tretter CP, Bubley GJ, Elfiky A, Park R, Stack EC, Signoretti S, Walsh MK, Steele G, Hirsch MS, Krajewski KM, Taplin ME, Rosenberg JE, Ross RW. A phase II multicenter study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy with pegfilgrastim support in patients (pts) muscle-invasive urothelial cancer (MIUC): Safety, pathologic, radiologic, and molecular correlates. J Clin Oncol. 2013 Feb 20; 31(6_suppl):278.
View in: PubMed

Elfiky AA, Jiang Z. The PI3 kinase signaling pathway in prostate cancer. Curr Cancer Drug Targets. 2013 Feb; 13(2):157-64.
View in: PubMed

Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2013 Feb 01; 31(4):412-9.
View in: PubMed

Nakabayashi M, Werner L, Courtney KD, Buckle G, Oh WK, Bubley GJ, Hayes JH, Weckstein D, Elfiky A, Sims DM, Kantoff PW, Taplin ME. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. BJU Int. 2012 Dec; 110(11):1729-35.
View in: PubMed

Elfiky AA, Sonpavde G. Novel molecular targets for the therapy of renal cell carcinoma. Discov Med. 2012 Jun; 13(73):461-71.
View in: PubMed

Elfiky AA, Aziz SA, Conrad PJ, Siddiqui S, Hackl W, Maira M, Robert CL, Kluger HM. Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer. J Transl Med. 2011 Aug 11; 9:133.
View in: PubMed

Hussain M, Smith MR, Sweeney C, Corn PG, Elfiky A, Gordon MS, Haas NB, Harzstark AL, Kurzrock R, Lara P, Lin C, Sella A, Small EJ, Spira AI, Vaishampayan UN, Vogelzang NJ, Scheffold C, Ballinger MD, Schimmoller F, Smith DC. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial. J Clin Oncol. 2011 May 20; 29(15_suppl):4516.
View in: PubMed

Elfiky AA, Cho DC, McDermott DF, Rosenberg JE, Fortner B, Antràs L, Chen K, Sheng Duh M, Jayawant SS, Oh WK, Atkins MB, Choueiri TK. Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma. Urol Oncol. 2011 Nov-Dec; 29(6):756-63.
View in: PubMed

Sonpavde G, Elfiky AA, Rosenberg JE. Novel agents for advanced bladder cancer. Ther Adv Med Oncol. 2009 Jul; 1(1):37-50.
View in: PubMed

Elfiky AA, Rosenberg JE. Targeting angiogenesis in bladder cancer. Curr Oncol Rep. 2009 May; 11(3):244-9.
View in: PubMed

Kelly WK, Halabi S, Elfiky A, Ou SS, Bogart J, Zelefsky M, Small E. Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811. Cancer. 2008 Dec 01; 113(11):3137-45.
View in: PubMed

Elfiky A, Saif MW, Beeram M, O' Brien S, Lammanna N, Castro JE, Woodworth J, Perea R, Storgard C, Von Hoff DD. BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: Phase I experience. J Clin Oncol. 2008 May 20; 26(15_suppl):2503.
View in: PubMed

Saif MW, Elfiky AA. Identifying and treating fluoropyrimidine-associated hand-and-foot syndrome in white and non-white patients. J Support Oncol. 2007 Jul-Aug; 5(7):337-43.
View in: PubMed

Elfiky AA, Saif MW. The developing trend of monoclonal antibodies in the treatment of colorectal cancer. Expert Opin Biol Ther. 2007 Jun; 7(6):871-83.
View in: PubMed

Saif MW, Elfiky A, Salem RR. Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol. 2007 Jun; 14(6):1860-9.
View in: PubMed

Saif MW, Elfiky A, Diasio R. Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. Clin Colorectal Cancer. 2006 Sep; 6(3):219-23.
View in: PubMed

Top